Explore chapters and articles related to this topic
ECT, epilepsy and obsessional personality style
Published in Alan Weiss, The Electroconvulsive Therapy Workbook, 2018
a partial response to desvenlafaxine 100 mg a day and quetiapine 100 mg at night. Initially ST found it challenging to engage in the psychological group programmes, preferring treatment individually. At the time of discharge she accepted a referral to the hospital day programme and follow-up with the psychiatrist.
Inhibitors of Human CYP2D6
Published in Shufeng Zhou, Cytochrome P450 2D6, 2018
Duloxetine coadministration increases the AUC and Cmax of desipramine 122% and 63% in humans, respectively (Skinner et al. 2003), while desvenlafaxine has only marginal effect on the exposure of desipramine (Patroneva et al. 2008). Sertraline results in an approximately 30%-44% elevation in plasma desipramine concentrations (Alderman et al. 1997b; Barros and Asnis 1993; Preskorn et al. 1994). Citalopram causes -50% increase in the AUC of desipramine (Gram et al. 1993).
Information on level of drugs into breastmilk
Published in Wendy Jones, Breastfeeding and Medication, 2018
There is limited information on transfer into breastmilk. Ilett et al. (2010) studied one mother who was keen to undertake partial breastfeeding on 250 mg desvenlafaxine daily and 100 mg amilsulpiride twice daily. Measurements on levels in milk and the plasma of mother and baby over a 24-hour period gave a relative infant dose of 6.1% for amisulpride. No abnormalities in development were noted in a paediatric assessment and the mother planned to continue partial breastfeeding.
Desvenlafaxine in the treatment of major depression: an updated overview
Published in Expert Opinion on Pharmacotherapy, 2021
Trevor R Norman, James S Olver
Desvenlafaxine is marketed for the treatment of major depression in a number of countries and there is considerable experience with its use in clinical practice. Its efficacy is based on multiple clinical trials, which have been extensively reviewed elsewhere [8,9]. The present article considers additional trials of desvenlafaxine in major depressive disorder.